Home / Advanced Search

  • Title/Keywords

  • Author/Affliations

  • Journal

  • Article Type

  • Start Year

  • End Year

Update SearchingClear
  • Articles
  • Online
Search Results (13)
  • Open Access

    ARTICLE

    Meiotic nuclear divisions 1 suppresses the proliferation and invasion of pancreatic cancer cells via regulating H2A.X variant histone

    DONGQIN WANG1,4, YAN SHI1, ZHIQIANG WANG4, JING ZHANG2, LUYAO WANG2, HONGYU MA3, SHUHUA SHI2, XIAOFU LIAN2, HUA HUANG4, XIAOJING WANG1,*, CHAOQUN LIAN4,*

    BIOCELL, Vol.48, No.1, pp. 111-122, 2024, DOI:10.32604/biocell.2023.046903

    Abstract Introduction: Among all malignant tumors of the digestive system, pancreatic carcinoma exhibits the highest mortality rate. Currently, prevention and effective treatment are urgent issues that need to be addressed. Methods: The study focused on meiotic nuclear divisions 1 (MND1), integrating data from the Gene Expression Profiling Interactive Analysis (GEPIA) database with prognostic survival analysis. Simultaneously, experiments at cellular level were employed to demonstrate the effect of MND1 on the proliferation and migration of PC. The small-molecule inhibitor of MND1 was used to suppress the migration of PC cells by knocking down MND1 using small interfering RNA (siRNA) in Patu-8988 and… More >

  • Open Access

    ARTICLE

    Pancreatic Cancer Data Classification with Quantum Machine Learning

    Amit Saxena1, Smita Saxena2,*

    Journal of Quantum Computing, Vol.5, pp. 1-13, 2023, DOI:10.32604/jqc.2023.044555

    Abstract Quantum computing is a promising new approach to tackle the complex real-world computational problems by harnessing the power of quantum mechanics principles. The inherent parallelism and exponential computational power of quantum systems hold the potential to outpace classical counterparts in solving complex optimization problems, which are pervasive in machine learning. Quantum Support Vector Machine (QSVM) is a quantum machine learning algorithm inspired by classical Support Vector Machine (SVM) that exploits quantum parallelism to efficiently classify data points in high-dimensional feature spaces. We provide a comprehensive overview of the underlying principles of QSVM, elucidating how different quantum feature maps and quantum… More >

  • Open Access

    ARTICLE

    Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data

    XUEFENG WANG1,#, SICONG JIANG2,#, XINHONG ZHOU3, XIAOFENG WANG4, LAN LI5, JIANJUN TANG1,*

    Oncology Research, Vol.31, No.5, pp. 697-714, 2023, DOI:10.32604/or.2023.029458

    Abstract Background: Pancreatic cancer is associated with high mortality and is one of the most aggressive of malignancies, but studies have not fully evaluated its molecular subtypes, prognosis and response to immunotherapy of different subtypes. The purpose of this study was to explore the molecular subtypes and the key genes associated with the prognosis of pancreas cancer patients and study the clinical phenotype, prognosis and response to immunotherapy using single-cell seq data and bulk RNA seq data, and data retrieved from GEO and TCGA databases. Methods: Single-cell seq data and bioinformatics methods were used in this study. Pancreatic cancer data were… More >

  • Open Access

    ARTICLE

    mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance

    CHIWEN BU1,2, LIGANG ZHAO1, LISHAN WANG1, ZEQIAN YU1, JIAHUA ZHOU1,*

    Oncology Research, Vol.31, No.4, pp. 495-503, 2023, DOI:10.32604/or.2023.029309

    Abstract Pancreatic cancer is one of the most aggressive cancers with a median survival time of less than 5 months, and conventional chemotherapeutics are the main treatment strategy. Poly(ADP-ribose) polymerase (PARP) inhibitors have been recently approved for BRCA1/2-mutant pancreatic cancer, opening a new era for targeted therapy for this disease. However, most pancreatic cancer patients carry wild-type BRCA1/2 with resistance to PARP inhibitors. Here, we reported that mammalian target of rapamycin complex 2 (mTORC2) kinase is overexpressed in pancreatic cancer tissues and promotes pancreatic cancer cell growth and invasion. Moreover, we found that knockdown of the mTORC2 obligate subunit Rictor sensitized… More > Graphic Abstract

    mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance

  • Open Access

    ARTICLE

    Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer

    XIN LI1,2,#, WENKAI JIANG3,#, WANCHENG LI3,#, SHI DONG3, YAN DU3, HUI ZHANG1,*, WENCE ZHOU1,3,*

    Oncology Research, Vol.31, No.4, pp. 505-514, 2023, DOI:10.32604/or.2023.026959

    Abstract Background: The dilemma of pancreatic cancer treatment has become a global challenge. For this reason, effective, feasible, and new medical methods are currently much-needed. Betulinic acid (BA) has been valued as a potential therapy for pancreatic cancer. However, the mechanism by which BA exerts an inhibitory effect on the development of pancreatic cancer remains elusive. Methods: A rat model and two cell models of pancreatic cancer were established, and the effect of BA on pancreatic cancer was verified in vivo and in vitro by using MTT, Transwell, flow cytometry, RT-PCR, Elisa and immunohistochemistry. At the same time, miR-365 inhibitors were… More > Graphic Abstract

    Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer

  • Open Access

    REVIEW

    Progress on diagnostic and prognostic markers of pancreatic cancer

    HONG YANG1,2, WAN LI1,2, LIWEN REN1,2, YIHUI YANG1,2, YIZHI ZHANG1,2, BINBIN GE1,2, SHA LI1,2, XIANGJIN ZHENG1,2, JINYI LIU1,2, SEN ZHANG1,2, GUANHUA DU1,2, BO TANG3, HONGQUAN WANG3, JINHUA WANG1,2,*

    Oncology Research, Vol.31, No.2, pp. 83-99, 2023, DOI:10.32604/or.2023.028905

    Abstract Pancreatic cancer is a malignant disease characterized by low survival and high recurrence rate, whose patients are mostly at the stage of locally advanced or metastatic disease when first diagnosed. Early diagnosis is particularly important because prognostic/predictive markers help guide optimal individualized treatment regimens. So far, CA19-9 is the only biomarker for pancreatic cancer approved by the FDA, but its effectiveness is limited by low sensitivity and specificity. With recent advances in genomics, proteomics, metabolomics, and other analytical and sequencing technologies, the rapid acquisition and screening of biomarkers is now possible. Liquid biopsy also occupies a significant place due to… More > Graphic Abstract

    Progress on diagnostic and prognostic markers of pancreatic cancer

  • Open Access

    ARTICLE

    Columbianetin acetate inhibits the occurrence and development of pancreatic cancer cells by down-regulating the expression of Meiotic nuclear divisions 1

    KANG SUN1, DONGQIN WANG1, ZHIQIANG ZHANG1, YINLONG HUANG3, XIAOFU LIAN3, JIALE HUA3, JING ZHANG3,*, CHAOQUN LIAN1,2,*

    BIOCELL, Vol.47, No.2, pp. 297-307, 2023, DOI:10.32604/biocell.2023.023553

    Abstract Columbianetin acetate (CE) is one of the effective components of Angelica pubescens. So far, the specific role and molecular mechanism of CE in pancreatic cancer are not clear. Thus, this study aimed to explore the specific mechanism of CE on pancreatic cancer. The target genes combined with CE were predicted through the PharmMapper database and the 3D molecular structure of CE. Then, the Cancer Genome Atlas (TCGA) and Cistrome data browser (DB) databases were used to screen Meiotic nuclear divisions 1 (MND1)-related genes, transcription factors, and transcription factor data sets, and the intersection of the above data sets. The “limma”… More >

  • Open Access

    ARTICLE

    Upregulation of Mobility in Pancreatic Cancer Cells by Secreted S100A11 Through Activation of Surrounding Fibroblasts

    Yosuke Mitsui*†, Nahoko Tomonobu*, Masami Watanabe, Rie Kinoshita*, I Wayan Sumardika*‡, Chen Youyi*, Hitoshi Murata*, Ken-ichi Yamamoto*, Takuya Sadahira, Acosta Gonzalez Herik Rodrigo*†, Hitoshi Takamatsu*, Kota Araki, Akira Yamauchi, Masahiro Yamamura#, Hideyo Fujiwara**, Yusuke Inoue††, Junichiro Futami‡‡, Ken Saito§§, Hidekazu Iioka§§, Eisaku Kondo§§, Masahiro Nishibori¶¶, Shinichi Toyooka§, Yasuhiko Yamamoto##, Yasutomo Nasu, Masakiyo Sakaguchi*

    Oncology Research, Vol.27, No.8, pp. 945-956, 2019, DOI:10.3727/096504019X15555408784978

    Abstract S100A11, a member of the S100 family of proteins, is actively secreted from pancreatic ductal adenocarcinoma (PDAC) cells. However, the role of the extracellular S100A11 in PDAC progression remains unclear. In the present study, we investigated the extracellular role of S100A11 in crosstalking between PDAC cells and surrounding fibroblasts in PDAC progression. An abundant S100A11 secreted from pancreatic cancer cells stimulated neighboring fibroblasts through receptor for advanced glycation end products (RAGE) upon S100A11 binding and was followed by not only an enhanced cancer cell motility in vitro but also an increased number of the PDAC-derived circulating tumor cells (CTCs) in… More >

  • Open Access

    ARTICLE

    Extracellular S100A11 Plays a Critical Role in Spread of the Fibroblast Population in Pancreatic Cancers

    Hitoshi Takamatsu*1, Ken-ichi Yamamoto*1, Nahoko Tomonobu*, Hitoshi Murata*, Yusuke Inoue, Akira Yamauchi, I Wayan Sumardika, Youyi Chen*, Rie Kinoshita*, Masahiro Yamamura, Hideyo Fujiwara#, Yosuke Mitsui*, **, Kota Araki*††, Junichiro Futami‡‡, Ken Saito§§, Hidekazu Iioka§§, I Made Winarsa Ruma§, Endy Widya Putranto¶¶, Masahiro Nishibori##, Eisaku Kondo§§, Yasuhiko Yamamoto***, Shinichi Toyooka††, Masakiyo Sakaguchi*

    Oncology Research, Vol.27, No.6, pp. 713-727, 2019, DOI:10.3727/096504018X15433161908259

    Abstract The fertile stroma in pancreatic ductal adenocarcinomas (PDACs) has been suspected to greatly contribute to PDAC progression. Since the main cell constituents of the stroma are fibroblasts, there is crosstalking(s) between PDAC cells and surrounding fibroblasts in the stroma, which induces a fibroblast proliferation burst. We have reported that several malignant cancer cells including PDAC cells secrete a pronounced level of S100A11, which in turn stimulates proliferation of cancer cells via the receptor for advanced glycation end products (RAGE) in an autocrine manner. Owing to the RAGE+ expression in fibroblasts, the extracellular abundant S100A11 will affect adjacent fibroblasts. In this… More >

  • Open Access

    ARTICLE

    Berberine inhibits the proliferation of pancreatic cancer cells by targeting pancreatic cancer stem cells through regulating EMT signaling pathway

    MENGMENG LIU1,#, YUE PAN1,2,#, XUFENG TAO1, WENLI KANG1, YINGJIE LIU1, YONGJIE YANG3,4,*, GARY GUISHAN XIAO1,*

    BIOCELL, Vol.46, No.10, pp. 2257-2265, 2022, DOI:10.32604/biocell.2022.020325

    Abstract Pancreatic ductal adenocarcinoma (PDAC) is universally acknowledged as the cancer with the highest mortality rate. Berberine has high medicinal value and has been used as an anti-cancer agent. Hence the purpose of this study was to investigate the anti-cancer effect of berberine in PDAC. Berberine was shown to have a selective anti-cancer effect on PDAC by MTT assay in vitro. Pancreatic cancer stem cells (PCSCs), regulated by epithelial–mesenchymal transition (EMT), could promote the proliferation of PDAC cells. However, berberine suppressed the proliferation and stemness of PCSCs through immunofluorescence staining, stem cell sphere assays and so forth in vitro. In vivo,… More >

Displaying 1-10 on page 1 of 13. Per Page